BioSpace1h
FDA Warns Applied Therapeutics of ‘Objectionable Conditions’ in Govorestat Study
The agency’s warning letter outlines Applied Therapeutics’ failure to provide adequate information regarding the clinical ...
BioSpace1h
Amylin Commands Weight-Loss Attention as Industry Anticipates Novo’s Phase III CagriSema Readout
Amylin analogs present a strong alternative or complement to GLP-1 receptor agonists, potentially eliciting higher-quality ...
BioSpace1h
Biopharma’s Shopping Spree, Applied Crashes on Rejection, Skysona’s Safety Concerns, More
Novartis, Gilead, Roche and Takeda commit to new partners in a spate of mid-sized collaborations this week. Meanwhile, ...
BioSpace1h
Sarepta, Biotech’s Regulatory Go-Getter, Signs Standout Rare Disease Deal
Not exactly known for its dealmaking, Sarepta Therapeutics has thrown down a massive wad of cash to work with Arrowhead ...
BioSpace16h
Roche Partners With COUR in Autoimmune Deal Potentially Worth More Than $900M
The collaboration will see COUR and Roche’s Genentech leverage the biotech’s antigen-specific immune tolerance platform to ...
BioSpace20h
Gilead Plots ADC Comeback With Potential $415M License Agreement
The deal with Tubulis will help Gilead regain its footing in the ADC space following the withdrawal of Trodelvy in bladder ...
BioSpace20h
Intra-Cellular Eyes Depression Approval for Caplyta as Stock Flies Under the Radar
Intra-Cellular submitted its application to the FDA for Caplyta’s approval in major depressive disorder, potentially opening ...
BioSpace22h
Takeda Puts Up to $1.3B on the Line for Keros’ Blood Cancer Anemia Drug
Keros’ elritercept has shown promising efficacy signals in myelofibrosis and myelodysplastic syndromes and could pose a ...
BioSpace23h
Alligator Axes 70% of Staff Amid ‘Capital Constraints,’ Renews Pancreatic Cancer Focus
Alongside the layoffs, Alligator will also suspend work on all of its earlier-stage assets and devote its resources to lead ...
BioSpace1d
Making the Grade: Drexel’s Biomedical Sciences Programs Boost Careers at All Stages
At Drexel University’s Graduate School of Biomedical Sciences and Professional Studies, graduate students and active ...
BioSpace1d
Novartis Pays Up to $2.9B in Huntington’s Deal With PTC
Monday’s agreement comes days after PTC discontinued the development of another asset, utreloxastat, due to disappointing ...
BioSpace2d
Bluebird’s Gene Therapy Skysona Under FDA Safety Probe for Hematologic Malignancies
The FDA last week announced that it is looking into the safety of bluebird bio ’s gene therapy Skysona (elivaldogene ...